My Companies
Notification
Account
Log Out
Login
On September 7, 2026, Novartis India approved and signed agreements to acquire Minipress and Minipres trademarks and related Indian intellectual property from Pfizer for ₹1,250 crore. Minipress XL generated ₹228.6 crore revenue and grew 6.3% CAGR, making this a transformative acquisition.
Evonile Pharma Board Approves ₹900 Crore Partly Paid Rights Issue
Evonile Pharma Board Approves ₹900 Crore Partly Paid Rights Issue
Novartis India Acquires Minipress Rights For ₹1,250 Crore
Novartis India Signs ₹10 Crore Exclusive Agreement For Retina Portfolio
Novartis India Terminates Dr Reddy’s Exclusive Distribution Agreement